Placebo News and Research

RSS

VSL#3 classified as refrigerated medical food for three GI conditions

As clinical studies continue to validate the use of probiotics to help promote general gastrointestinal health, a growing U.S. market for probiotics indicates that the U.S. healthcare community and consumers alike are recognizing the value of these beneficial microorganisms. However, because most probiotics are classified as dietary supplements, directing patients to the best probiotic for their individual needs can be challenging.

18 Nov 2011

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

Multivitamin use linked to less healthy behaviors

The lack of evidence on multivitamin health benefits is no impediment to their widespread popularity, with over half the U.S. population popping such pills. This translates into a $27 billion industry, which lures consumers with the illusory promise of better health. But shocking new research suggests taking multivitamins might have the opposite effect -- not simply on the metabolic level, but on a metaphysical one: promoting a false sense of invulnerability that actually leads users to engage in riskier behaviors.

17 Nov 2011

Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

Additional results from BioSante's LibiGel pK study on HSDD

BioSante Pharmaceuticals, Inc., today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Top line data from this study were announced on September 12, 2011.

16 Nov 2011

First clinical trial of dapivirine-maraviroc ring to treat HIV in women

In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.

16 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and stroke.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease.

16 Nov 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function.

15 Nov 2011

Stem cell injections within two weeks may not help in post heart attack recovery

University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance-just not as they originally thought.

15 Nov 2011

Researchers explore how design of chronic and acute pain trials might be improved

For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.

15 Nov 2011

PROMETAT no more effective than placebo in reducing methamphetamine use

A recent study has found that PROMETAT, a popular but controversial treatment for methamphetamine addiction, is no more effective than placebo in reducing methamphetamine use, keeping users in treatment, or reducing cravings for methamphetamine.

15 Nov 2011

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.

15 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Placebo News and Research

VSL#3 classified as refrigerated medical food for three GI conditions

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Multivitamin use linked to less healthy behaviors

Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Additional results from BioSante's LibiGel pK study on HSDD

First clinical trial of dapivirine-maraviroc ring to treat HIV in women

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

Stem cell injections within two weeks may not help in post heart attack recovery

Researchers explore how design of chronic and acute pain trials might be improved

PROMETAT no more effective than placebo in reducing methamphetamine use

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News